

Clerk of the House of Representatives  
 Legislative Resource Center  
 B-106 Cannon Building  
 Washington, DC 20515

Secretary of the Senate  
 Office of Public Records  
 232 Hart Building  
 Washington, DC 20510

RECEIVED  
 SECRETARY OF THE SENATE  
 PUBLIC RECORDS  
 01 FEB 14 PM 2:03

# LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required To Complete This Page

|   |                           |                   |                |
|---|---------------------------|-------------------|----------------|
| 1. Registrant Name<br>Bennett, Turner & Coleman, LLP  |                           |                   |                |
| 2. Address <input type="checkbox"/> Check if different than previously reported<br>1900 K Street NW, Suite 750 Washington, DC 20006 |                           |                   |                |
| 3. Principal Place of Business (if different from line 2)<br>City: _____ State/Zip (or Country): _____                              |                           |                   |                |
| 4. Contact Name<br>Albert Cacoza  | Telephone<br>202-833-4500 | E-mail (optional) | 5. Senate ID # |
| 7. Client Name <input type="checkbox"/> Self<br>Novartis Pharmaceuticals Corporation  |                           |                   | 6. House ID #  |

**TYPE OF REPORT** 8. Year 2000 Midyear (January 1-June 30)  OR Year End (July 1-December 31)

9. Check if this filing amends a previously filed version of this report

10. Check if this is a Termination Report  ⇒ Termination Date \_\_\_\_\_ 11. No Lobbying Activity

| INCOME OR EXPENSES - Complete Either Line 12 OR Line 13   |  |
|---|--|
| <p><b>12. Lobbying Firms</b></p> <p>INCOME relating to lobbying activities for this reporting period was:</p> <p>Less than \$10,000 <input checked="" type="checkbox"/></p> <p>\$10,000 or more <input type="checkbox"/> ⇒ \$ _____<br/> <small>Income (nearest \$20,000)</small></p> <p>Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).</p> | <p><b>13. Organizations</b></p> <p>EXPENSES relating to lobbying activities for this reporting period were:</p> <p>Less than \$10,000 <input type="checkbox"/></p> <p>\$10,000 or more <input type="checkbox"/> ⇒ \$ _____<br/> <small>Expenses (nearest \$20,000)</small></p> <p><b>14. REPORTING METHOD.</b> Check box to indicate expense accounting method. See instructions for description of options.</p> <p><input checked="" type="checkbox"/> Method A. Reporting amounts using LDA definitions only</p> <p><input type="checkbox"/> Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code</p> <p><input type="checkbox"/> Method C. Reporting amounts under section 162(e) of the Internal Revenue Code</p> |

Signature \_\_\_\_\_

Printed Name and Title Terry S. Coleman, Partner

Registrant Name Bennett, Turner & Coleman, LLP Client Name Novartis Pharmaceuticals Corporation

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code MMM (one per page)

16. Specific lobbying issues

Medicare reimbursement for oral anti-cancer drugs

17. House(s) of Congress and Federal agencies contacted  Check if None

U.S. House of Representatives  
U.S. Senate

18. Name of each individual who acted as a lobbyist in this issue area

| Name                    | Covered Official Position (if applicable) | New                      |
|-------------------------|---|--------------------------|
| Sam Turner, Partner     |   | <input type="checkbox"/> |
| Elizabeth Goss, Partner |   | <input type="checkbox"/> |
|                         |   | <input type="checkbox"/> |
|                         |   | <input type="checkbox"/> |
|                         |   | <input type="checkbox"/> |
|                         |   | <input type="checkbox"/> |
|                         |   | <input type="checkbox"/> |
|                         |   | <input type="checkbox"/> |

19. Interest of each foreign entity in the specific issues listed on line 16 above  Check if None

To the degree that public policies, either laws or regulations, commercially benefit Novartis Pharmaceuticals Corporation, so too Novartis AG will benefit. Novartis AG is the parent company of Novartis Pharmaceuticals Corporation and the parent benefits in the commercial success of its subsidiary.

Signature *Terry S. Coleman* Date February 13, 2001

Printed Name and Title Terry S. Coleman, Partner